Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 06:27 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableUnknownINTERVENTIONAL

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

ClinicalTrials.gov · NCT02118376 · Registry updated: 2014-04-21

Condition / research focus: Obesity
Sponsor: Shanghai 10th People's Hospital
Countries with listed sites: China
Registry dates and results: Start: 2014-08. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Shanghai Tenth People' Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

ClinicalTrials.gov · NCT01843127 · Registry updated: 2014-03-31

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Gilead Sciences
Countries with listed sites: United States
Registry dates and results: Start: 2013-04. Completion: 2013-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ranolazine (drug)
Placebo (drug)
Exenatide (drug)

Where the study takes place — 3 listed sites

Profil Institute for Clinical Research, Inc.
Chula Vista, California, United States
Site recruitment: Not reported
SeaView Research, Inc
Miami, Florida, United States
Site recruitment: Not reported
Translational Research Institute-Florida Hospital
Orlando, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT02059564 · Registry updated: 2014-02-11

Condition / research focus: Diabetes Mellitus
Sponsor: Hanmi Pharmaceutical Company Limited
Countries with listed sites: United States
Registry dates and results: Start: 2013-12. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HM11260C (drug) — also listed as: LAPS-Exendin-4
Placebo (drug) — also listed as: Normal saline solution
Victoza (drug) — also listed as: Liraglutide

Where the study takes place — 1 listed sites

Hanmi
California City, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of HM11260C in Healthy Male Subject

ClinicalTrials.gov · NCT01093729 · Registry updated: 2014-02-07

Condition / research focus: Healthy
Sponsor: Hanmi Pharmaceutical Company Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-02. Completion: 2010-10 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HM11260C (drug)
HM11260C (drug)
HM11260C (drug)
HM11260C (drug)
HM11260C (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

ClinicalTrials.gov · NCT01818648 · Registry updated: 2014-01-14

Condition / research focus: Short Bowel Syndrome
Sponsor: Mayo Clinic
Countries with listed sites: No country reported
Registry dates and results: Start: 2013-03. Completion: 2014-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

ClinicalTrials.gov · NCT00546728 · Registry updated: 2013-11-08

Condition / research focus: Impaired Glucose Tolerance
Sponsor: St. Paul Heart Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2007-10. Completion: 2011-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)
Metformin (drug)

Where the study takes place — 2 listed sites

International Diabetes Center at Park Nicollet
Saint Louis Park, Minnesota, United States
Site recruitment: Not reported
St. Paul Heart Clinic
Saint Paul, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

ClinicalTrials.gov · NCT01783717 · Registry updated: 2013-10-22

Condition / research focus: Hypothalamic Obesity; Diabetes Mellitus
Sponsor: Huashan Hospital
Countries with listed sites: China
Registry dates and results: Start: 2012-12. Completion: 2015-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

Department of Endocrinology and Metabolism
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

ClinicalTrials.gov · NCT01147627 · Registry updated: 2013-08-21

Condition / research focus: Diabetes Mellitus, Type 2; Newly Diagnosed
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2010-08. Completion: 2012-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide injection (drug) — also listed as: Byetta®(Eli Lilly and Company)
Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R (drug) — also listed as: Humalog Mix 25®（Eli Lilly and Company)
Pioglitazone (drug)

Where the study takes place — 25 listed sites

China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University People's Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University First Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The Military General Hospital of Beijing PLA
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The Second Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Qingyuan People's hospital
Qingyuan, Guangdong, China
Site recruitment: Not reported
The first Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
Site recruitment: Not reported
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
Affiliated hospital of Guangdong medical college
Zhanjiang, Guangdong, China
Site recruitment: Not reported
The first affiliated hospital of Guangxi Medical College
Nanning, Guangxi, China
Site recruitment: Not reported
The Affiliated Hospital of Guiyang Medical College
Guiyang, Guizhou, China
Site recruitment: Not reported
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Not reported
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Second Xiangya Hospital of Central-south University
Changsha, Hunan, China
Site recruitment: Not reported
The Affiliated Hospital of Inner Mangolia Medical College
Hohhot, Inner Mongolia, China
Site recruitment: Not reported
Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Site recruitment: Not reported
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Zhongda Hospital of Southeast University
Nanjing, Jiangsu, China
Site recruitment: Not reported
China Medical University
Shenyang, Liaoning, China
Site recruitment: Not reported
Xijing Hospital of The Fourth Military Medical University
Xi'an, Shaanxi, China
Site recruitment: Not reported
The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China
Site recruitment: Not reported
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects

ClinicalTrials.gov · NCT01156779 · Registry updated: 2013-08-13

Condition / research focus: Diabetes Mellitus
Sponsor: Dong-A Pharmaceutical Co., Ltd.
Countries with listed sites: South Korea
Registry dates and results: Start: 2010-07. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SR-exenatide (drug) — also listed as: DA-3091

Where the study takes place — 1 listed sites

Clinical Trial center, Clinical Research institute, Seoul National University Hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients

ClinicalTrials.gov · NCT01473147 · Registry updated: 2013-07-30

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Chang Gung Memorial Hospital
Countries with listed sites: Taiwan
Registry dates and results: Start: 2011-10. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Normal saline (drug)

Where the study takes place — 1 listed sites

Chang Gung Memorial Hospital
Taoyuan, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide

ClinicalTrials.gov · NCT00964262 · Registry updated: 2013-07-19

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Peptron, Inc.
Countries with listed sites: South Korea
Registry dates and results: Start: 2009-08. Completion: 2010-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SR Exenatide (PT302) (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Clinical Trials Center, Seoul National University Hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

ClinicalTrials.gov · NCT01270191 · Registry updated: 2013-06-27

Condition / research focus: Type 2 Diabetes
Sponsor: Taipei Veterans General Hospital, Taiwan
Countries with listed sites: Taiwan
Registry dates and results: Start: 2010-11. Completion: 2015-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Humulin-N (drug) — also listed as: NPH insulin

Where the study takes place — 1 listed sites

Taipei Veterans General Hospital
Taipei, Taipei, Taiwan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

ClinicalTrials.gov · NCT01798264 · Registry updated: 2013-05-17

Condition / research focus: Type 2 Diabetes
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2009-02. Completion: 2009-05 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 (exenatide in DUROS) (drug)

Where the study takes place — 3 listed sites

Facility not reported
Miami Gardens, Florida, United States
Site recruitment: Not reported
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States
Site recruitment: Not reported
dGd Research
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

ClinicalTrials.gov · NCT00667732 · Registry updated: 2013-02-06

Condition / research focus: Type 2 Diabetes
Sponsor: Oregon Health and Science University
Countries with listed sites: United States
Registry dates and results: Start: 2007-03. Completion: 2010-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta
placebo (drug)

Where the study takes place — 3 listed sites

Medstar Research Institute
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported
Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

ClinicalTrials.gov · NCT01455883 · Registry updated: 2012-12-25

Condition / research focus: Type 2 Diabetes
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2014-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 60 mcg/day (drug)
glimepiride (drug)

Where the study takes place — 1 listed sites

Intarcia Therapeutics, Inc
Hayward, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

ClinicalTrials.gov · NCT01455909 · Registry updated: 2012-12-25

Condition / research focus: Type 2 Diabetes
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2014-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 60 mcg/day (drug)
sitagliptin (drug)

Where the study takes place — 1 listed sites

Intarcia Therapeutics, Inc
Hayward, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

ClinicalTrials.gov · NCT01455922 · Registry updated: 2012-12-25

Condition / research focus: Type 2 Diabetes
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2014-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 (drug)
glimepiride (drug)

Where the study takes place — 1 listed sites

Intarcia Therapeutics, Inc
Hayward, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

ClinicalTrials.gov · NCT00845559 · Registry updated: 2012-12-11

Condition / research focus: Obesity; Insulin Resistance; Impaired Glucose Tolerance; Cardiovascular Disease
Sponsor: Yale University
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-08. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

ClinicalTrials.gov · NCT00886626 · Registry updated: 2012-10-29

Condition / research focus: Obesity, Morbid
Sponsor: University of Minnesota
Countries with listed sites: United States
Registry dates and results: Start: 2009-05. Completion: 2011-02 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

University of Minnesota
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Physical and Chemical Study of Atherosclerosis Mechanisms

ClinicalTrials.gov · NCT01700075 · Registry updated: 2012-10-04

Condition / research focus: Myocardial Infarction; Coronary Artery Diseases; Diabetes Mellitus, Type 2; Atherosclerosis of Femoral Artery
Sponsor: Nazarbayev University
Countries with listed sites: Kazakhstan
Registry dates and results: Start: 2009-01. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Conventional treatment (drug) — also listed as: Pathogenetic and symptomatic treatment
Weight loss treatment (dietary_supplement) — also listed as: vegetable and salt diet

Where the study takes place — 1 listed sites

Scientific Research Institute of Cardiology and Internal Diseases
Almaty, Kazakhstan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 06:27 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableUnknownINTERVENTIONAL

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

ClinicalTrials.gov · NCT02118376 · Registry updated: 2014-04-21

Condition / research focus: Obesity
Sponsor: Shanghai 10th People's Hospital
Countries with listed sites: China
Registry dates and results: Start: 2014-08. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

Shanghai Tenth People' Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

ClinicalTrials.gov · NCT01843127 · Registry updated: 2014-03-31

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Gilead Sciences
Countries with listed sites: United States
Registry dates and results: Start: 2013-04. Completion: 2013-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ranolazine (drug)
Placebo (drug)
Exenatide (drug)

Where the study takes place — 3 listed sites

Profil Institute for Clinical Research, Inc.
Chula Vista, California, United States
Site recruitment: Not reported
SeaView Research, Inc
Miami, Florida, United States
Site recruitment: Not reported
Translational Research Institute-Florida Hospital
Orlando, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT02059564 · Registry updated: 2014-02-11

Condition / research focus: Diabetes Mellitus
Sponsor: Hanmi Pharmaceutical Company Limited
Countries with listed sites: United States
Registry dates and results: Start: 2013-12. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HM11260C (drug) — also listed as: LAPS-Exendin-4
Placebo (drug) — also listed as: Normal saline solution
Victoza (drug) — also listed as: Liraglutide

Where the study takes place — 1 listed sites

Hanmi
California City, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of HM11260C in Healthy Male Subject

ClinicalTrials.gov · NCT01093729 · Registry updated: 2014-02-07

Condition / research focus: Healthy
Sponsor: Hanmi Pharmaceutical Company Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-02. Completion: 2010-10 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HM11260C (drug)
HM11260C (drug)
HM11260C (drug)
HM11260C (drug)
HM11260C (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

ClinicalTrials.gov · NCT01818648 · Registry updated: 2014-01-14

Condition / research focus: Short Bowel Syndrome
Sponsor: Mayo Clinic
Countries with listed sites: No country reported
Registry dates and results: Start: 2013-03. Completion: 2014-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

ClinicalTrials.gov · NCT00546728 · Registry updated: 2013-11-08

Condition / research focus: Impaired Glucose Tolerance
Sponsor: St. Paul Heart Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2007-10. Completion: 2011-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)
Metformin (drug)

Where the study takes place — 2 listed sites

International Diabetes Center at Park Nicollet
Saint Louis Park, Minnesota, United States
Site recruitment: Not reported
St. Paul Heart Clinic
Saint Paul, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

ClinicalTrials.gov · NCT01783717 · Registry updated: 2013-10-22

Condition / research focus: Hypothalamic Obesity; Diabetes Mellitus
Sponsor: Huashan Hospital
Countries with listed sites: China
Registry dates and results: Start: 2012-12. Completion: 2015-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

Department of Endocrinology and Metabolism
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

ClinicalTrials.gov · NCT01147627 · Registry updated: 2013-08-21

Condition / research focus: Diabetes Mellitus, Type 2; Newly Diagnosed
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2010-08. Completion: 2012-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide injection (drug) — also listed as: Byetta®(Eli Lilly and Company)
Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R (drug) — also listed as: Humalog Mix 25®（Eli Lilly and Company)
Pioglitazone (drug)

Where the study takes place — 25 listed sites

China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University People's Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University First Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The Military General Hospital of Beijing PLA
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The Second Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Qingyuan People's hospital
Qingyuan, Guangdong, China
Site recruitment: Not reported
The first Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
Site recruitment: Not reported
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
Affiliated hospital of Guangdong medical college
Zhanjiang, Guangdong, China
Site recruitment: Not reported
The first affiliated hospital of Guangxi Medical College
Nanning, Guangxi, China
Site recruitment: Not reported
The Affiliated Hospital of Guiyang Medical College
Guiyang, Guizhou, China
Site recruitment: Not reported
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Not reported
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Second Xiangya Hospital of Central-south University
Changsha, Hunan, China
Site recruitment: Not reported
The Affiliated Hospital of Inner Mangolia Medical College
Hohhot, Inner Mongolia, China
Site recruitment: Not reported
Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Site recruitment: Not reported
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Zhongda Hospital of Southeast University
Nanjing, Jiangsu, China
Site recruitment: Not reported
China Medical University
Shenyang, Liaoning, China
Site recruitment: Not reported
Xijing Hospital of The Fourth Military Medical University
Xi'an, Shaanxi, China
Site recruitment: Not reported
The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China
Site recruitment: Not reported
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects

ClinicalTrials.gov · NCT01156779 · Registry updated: 2013-08-13

Condition / research focus: Diabetes Mellitus
Sponsor: Dong-A Pharmaceutical Co., Ltd.
Countries with listed sites: South Korea
Registry dates and results: Start: 2010-07. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SR-exenatide (drug) — also listed as: DA-3091

Where the study takes place — 1 listed sites

Clinical Trial center, Clinical Research institute, Seoul National University Hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients

ClinicalTrials.gov · NCT01473147 · Registry updated: 2013-07-30

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Chang Gung Memorial Hospital
Countries with listed sites: Taiwan
Registry dates and results: Start: 2011-10. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Normal saline (drug)

Where the study takes place — 1 listed sites

Chang Gung Memorial Hospital
Taoyuan, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide

ClinicalTrials.gov · NCT00964262 · Registry updated: 2013-07-19

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Peptron, Inc.
Countries with listed sites: South Korea
Registry dates and results: Start: 2009-08. Completion: 2010-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SR Exenatide (PT302) (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Clinical Trials Center, Seoul National University Hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

ClinicalTrials.gov · NCT01270191 · Registry updated: 2013-06-27

Condition / research focus: Type 2 Diabetes
Sponsor: Taipei Veterans General Hospital, Taiwan
Countries with listed sites: Taiwan
Registry dates and results: Start: 2010-11. Completion: 2015-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Humulin-N (drug) — also listed as: NPH insulin

Where the study takes place — 1 listed sites

Taipei Veterans General Hospital
Taipei, Taipei, Taiwan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

ClinicalTrials.gov · NCT01798264 · Registry updated: 2013-05-17

Condition / research focus: Type 2 Diabetes
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2009-02. Completion: 2009-05 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 (exenatide in DUROS) (drug)

Where the study takes place — 3 listed sites

Facility not reported
Miami Gardens, Florida, United States
Site recruitment: Not reported
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States
Site recruitment: Not reported
dGd Research
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

ClinicalTrials.gov · NCT00667732 · Registry updated: 2013-02-06

Condition / research focus: Type 2 Diabetes
Sponsor: Oregon Health and Science University
Countries with listed sites: United States
Registry dates and results: Start: 2007-03. Completion: 2010-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta
placebo (drug)

Where the study takes place — 3 listed sites

Medstar Research Institute
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported
Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

ClinicalTrials.gov · NCT01455883 · Registry updated: 2012-12-25

Condition / research focus: Type 2 Diabetes
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2014-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 60 mcg/day (drug)
glimepiride (drug)

Where the study takes place — 1 listed sites

Intarcia Therapeutics, Inc
Hayward, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

ClinicalTrials.gov · NCT01455909 · Registry updated: 2012-12-25

Condition / research focus: Type 2 Diabetes
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2014-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 60 mcg/day (drug)
sitagliptin (drug)

Where the study takes place — 1 listed sites

Intarcia Therapeutics, Inc
Hayward, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

ClinicalTrials.gov · NCT01455922 · Registry updated: 2012-12-25

Condition / research focus: Type 2 Diabetes
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2014-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 (drug)
glimepiride (drug)

Where the study takes place — 1 listed sites

Intarcia Therapeutics, Inc
Hayward, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

ClinicalTrials.gov · NCT00845559 · Registry updated: 2012-12-11

Condition / research focus: Obesity; Insulin Resistance; Impaired Glucose Tolerance; Cardiovascular Disease
Sponsor: Yale University
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-08. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

ClinicalTrials.gov · NCT00886626 · Registry updated: 2012-10-29

Condition / research focus: Obesity, Morbid
Sponsor: University of Minnesota
Countries with listed sites: United States
Registry dates and results: Start: 2009-05. Completion: 2011-02 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta

Where the study takes place — 1 listed sites

University of Minnesota
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Physical and Chemical Study of Atherosclerosis Mechanisms

ClinicalTrials.gov · NCT01700075 · Registry updated: 2012-10-04

Condition / research focus: Myocardial Infarction; Coronary Artery Diseases; Diabetes Mellitus, Type 2; Atherosclerosis of Femoral Artery
Sponsor: Nazarbayev University
Countries with listed sites: Kazakhstan
Registry dates and results: Start: 2009-01. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Conventional treatment (drug) — also listed as: Pathogenetic and symptomatic treatment
Weight loss treatment (dietary_supplement) — also listed as: vegetable and salt diet

Where the study takes place — 1 listed sites

Scientific Research Institute of Cardiology and Internal Diseases
Almaty, Kazakhstan
Site recruitment: Not reported

Original record, eligibility, contacts and results →